27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth

Cell Reports

Volumn 5, Issue 3, 2013, Pages 637-645

  Wu, Qian ^a   Ishikawa, Tomonori ^a   Sirianni, Rosa ^a   Tang, Hao ^b   McDonald, Jeffrey G ^a   Yuhanna, Ivan S ^a   Thompson, Bonne ^a   Girard, Luc ^a   Mineo, Chieko ^a   Brekken, Rolf A ^a   Umetani, Michihisa ^a   Euhus, David M ^a   Xie, Yang ^b   Shaul, Philip W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

26 HYDROXYCHOLESTEROL; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTEROL; CYTOCHROME P450; CYTOCHROME P450 7B1; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PROTEIN RET; UNCLASSIFIED DRUG; 27-HYDROXYCHOLESTEROL; CHOLESTEROL DERIVATIVE; CYP7B1 PROTEIN, HUMAN; STEROID MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION; UTERUS WEIGHT; ANIMAL; BIOSYNTHESIS; BLOOD; BREAST TUMOR; CELL GROWTH; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

MUS;

ANIMALS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HETEROGRAFTS; HUMANS; HYDROXYCHOLESTEROLS; MCF-7 CELLS; MICE; MICE, SCID; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; STEROID HYDROXYLASES;

EID: 84887617570     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.10.006     Document Type: Article

References (38)

1. Althuis M.D., Fergenbaum J.H., Garcia-Closas M., Brinton L.A., Madigan M.P., Sherman M.E. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol. Biomarkers Prev. 2004, 13:1558-1568.
2. Bianchini F., Kaaks R., Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002, 3:565-574.
3. Brown A.J., Jessup W. Oxysterols and atherosclerosis. Atherosclerosis 1999, 142:1-28.
4. Burkard I., von Eckardstein A., Waeber G., Vollenweider P., Rentsch K.M. Lipoprotein distribution and biological variation of 24S- and 27-hydroxycholesterol in healthy volunteers. Atherosclerosis 2007, 194:71-78.
5. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N.Engl. J. Med. 2003, 348:1625-1638.
6. Chambliss K.L., Wu Q., Oltmann S., Konaniah E.S., Umetani M., Korach K.S., Thomas G.D., Mineo C., Yuhanna I.S., Kim S.H., et al. Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J.Clin. Invest. 2010, 120:2319-2330.
7. Chen S., Masri S., Wang X., Phung S., Yuan Y.C., Wu X. What do we know about the mechanisms of aromatase inhibitor resistance?. J.Steroid Biochem. Mol. Biol. 2006, 102:232-240.
8. Cleary M.P., Grossmann M.E., Ray A. Effect of obesity on breast cancer development. Vet. Pathol. 2010, 47:202-213.
9. Dunbier A.K., Anderson H., Ghazoui Z., Lopez-Knowles E., Pancholi S., Ribas R., Drury S., Sidhu K., Leary A., Martin L.A., Dowsett M. ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1. PLoS Genet. 2011, 7:e1001382.
10. DuSell C.D., Umetani M., Shaul P.W., Mangelsdorf D.J., McDonnell D.P. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol. Endocrinol. 2008, 22:65-77.
11. Dzeletovic S., Breuer O., Lund E., Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal. Biochem. 1995, 225:73-80.
12. El Roz A., Bard J.M., Huvelin J.M., Nazih H. LXR agonists and ABCG1-dependent cholesterol efflux in MCF-7 breast cancer cells: relation to proliferation and apoptosis. Anticancer Res. 2012, 32:3007-3013.
13. Furberg A.S., Veierød M.B., Wilsgaard T., Bernstein L., Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J.Natl. Cancer Inst. 2004, 96:1152-1160.
14. Gu J.W., Young E., Patterson S.G., Makey K.L., Wells J., Huang M., Tucker K.B., Miele L. Postmenopausal obesity promotes tumor angiogenesis and breast cancer progression in mice. Cancer Biol. Ther. 2011, 11:910-917.
15. Hansson M., Ellis E., Hunt M.C., Schmitz G., Babiker A. Marked induction of sterol 27-hydroxylase activity and mRNA levels during differentiation of human cultured monocytes into macrophages. Biochim. Biophys. Acta 2003, 1593:283-289.
16. Janowski B.A., Grogan M.J., Jones S.A., Wisely G.B., Kliewer S.A., Corey E.J., Mangelsdorf D.J. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl. Acad. Sci. USA 1999, 96:266-271.
17. Jensen E.V., Jordan V.C. The estrogen receptor: a model for molecular medicine. Clin. Cancer Res. 2003, 9:1980-1989.
18. Labhart P., Karmakar S., Salicru E.M., Egan B.S., Alexiadis V., O'Malley B.W., Smith C.L. Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator. Proc. Natl. Acad. Sci. USA 2005, 102:1339-1344.
19. Lappano R., Recchia A.G., De Francesco E.M., Angelone T., Cerra M.C., Picard D., Maggiolini M. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor α-mediated signaling in cancer cells and in cardiomyocytes. PLoS ONE 2011, 6:e16631.
20. Lerman L.O., Chade A.R., Sica V., Napoli C. Animal models of hypertension: an overview. J.Lab. Clin. Med. 2005, 146:160-173.
21. Li-Hawkins J., Lund E.G., Turley S.D., Russell D.W. Disruption of the oxysterol 7alpha-hydroxylase gene in mice. J.Biol. Chem. 2000, 275:16536-16542.
22. Llaverias G., Danilo C., Mercier I., Daumer K., Capozza F., Williams T.M., Sotgia F., Lisanti M.P., Frank P.G. Role of cholesterol in the development and progression of breast cancer. Am. J. Pathol. 2011, 178:402-412.
23. McDonald J.G., Smith D.D., Stiles A.R., Russell D.W. A comprehensive method for extraction and quantitative analysis of sterols and secosteroids from human plasma. J.Lipid Res. 2012, 53:1399-1409.
24. McPherson K., Steel C.M., Dixon J.M. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000, 321:624-628.
25. Michalaki V., Koutroulis G., Syrigos K., Piperi C., Kalofoutis A. Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol. Cell. Biochem. 2005, 268:19-24.
26. Morandi A., Plaza-Menacho I., Isacke C.M. RET in breast cancer: functional and therapeutic implications. Trends Mol. Med. 2011, 17:149-157.
27. Nunez N.P., Perkins S.N., Smith N.C., Berrigan D., Berendes D.M., Varticovski L., Barrett J.C., Hursting S.D. Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr. Cancer 2008, 60:534-541.
28. Patel R.R., Sharma C.G., Jordan V.C. Optimizing the antihormonal treatment and prevention of breast cancer. Breast Cancer 2007, 14:113-122.
29. Qiu R.G., Abo A., Steven Martin G. A human homolog of the C. elegans polarity determinant Par-6 links Rac and Cdc42 to PKCzeta signaling and cell transformation. Curr. Biol. 2000, 10:697-707.
30. Reaven G.M. Why Syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab. 2005, 1:9-14.
31. Russell D.W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 2003, 72:137-174.
32. Sun J., Huang Y.R., Harrington W.R., Sheng S., Katzenellenbogen J.A., Katzenellenbogen B.S. Antagonists selective for estrogen receptor alpha. Endocrinology 2002, 143:941-947.
33. Tang W., Pettersson H., Norlin M. Involvement of the PI3K/Akt pathway in estrogen-mediated regulation of human CYP7B1: identification of CYP7B1 as a novel target for PI3K/Akt and MAPK signalling. J.Steroid Biochem. Mol. Biol. 2008, 112:63-73.
34. Umetani M., Domoto H., Gormley A.K., Yuhanna I.S., Cummins C.L., Javitt N.B., Korach K.S., Shaul P.W., Mangelsdorf D.J. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 2007, 13:1185-1192.
35. Vedin L.L., Lewandowski S.A., Parini P., Gustafsson J.A., Steffensen K.R. The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. Carcinogenesis 2009, 30:575-579.
36. Vollmer G. Endometrial cancer: experimental models useful for studies on molecular aspects of endometrial cancer and carcinogenesis. Endocr. Relat. Cancer 2003, 10:23-42.
37. Yamamoto Y., Moore R., Hess H.A., Guo G.L., Gonzalez F.J., Korach K.S., Maronpot R.R., Negishi M. Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. J.Biol. Chem. 2006, 281:16625-16631.
38. Zhang Y., Breevoort S.R., Angdisen J., Fu M., Schmidt D.R., Holmstrom S.R., Kliewer S.A., Mangelsdorf D.J., Schulman I.G. Liver LXRαexpression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J.Clin. Invest. 2012, 122:1688-1699.